Drugs / Succinylated gelatin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04637308 | Sep 2019 → Sep 2020 | — | Guangdong Provincial People's Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02631356 Comparator | Nov 2015 → May 2016 | — | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Succinylated gelatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02631356 ↗ |
| Known as | Gelofusine | “Succinylated gelatin (SG, "Gelofusine"; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular...” NCT04637308 ↗ |
| Route | Intravenous | “received intravenous infusion of succinylated gelatin” NCT04637308 ↗ |